Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2513062 | 1.00 | KMT2A (0.49) | KMT2AMEN1MMP13STSALDH1A1 | |
| SCHEMBL20099653 | 0.94 | KMT2A (0.50) | KMT2AMEN1MMP13STSALDH1A1 | |
| SCHEMBL18397145 | 0.90 | KMT2A (0.51) | KMT2AMEN1MMP13STSALDH1A1 | |
| SCHEMBL18137607 | 0.88 | KMT2A (0.54) | KMT2AMEN1MMP13STSALDH1A1 | |
| SCHEMBL1250612 | 0.84 | ALDH1A1 (0.53) | KMT2AMEN1ALDH1A1MAPTTDP1 | |
| SCHEMBL1250614 | 0.84 | ALDH1A1 (0.53) | KMT2AMEN1ALDH1A1MAPTTDP1 | |
| SCHEMBL23348324 | 0.84 | STS (0.57) | MMP13STSALDH1A1MAPT | |
| SCHEMBL28527952 | 0.81 | KMT2A (0.50) | KMT2AMEN1MMP13STSALDH1A1 | |
| SCHEMBL25408371 | 0.81 | KMT2A (0.46) | KMT2AMEN1MMP13STSALDH1A1 | |
| SCHEMBL26738605 | 0.81 | KMT2A (0.46) | KMT2AMEN1MMP13STSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178554-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2012-05-15 | — | — | US | disclosed |
| US-8148540-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | ASTRAZENECA (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20110245254-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-06 | — | — | US | disclosed |
| US-20110213147-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2011-09-01 | — | — | US | disclosed |
| US-20110021772-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2011-01-27 | — | — | US | disclosed |
| US-7732610-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. (FR) | 2010-06-08 | — | — | US | disclosed |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | NOVEXEL (FR) | 2010-02-25 | — | — | US | disclosed |
| US-7638529-B2 | anti-bacterial agents; staphylococci; coliform bacteria; 7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide; bridged bicyclic ureas or carbamates having bridgehead nitrogen | AVENTIS PHARMA S.A. (FR) | 2009-12-29 | — | — | US | disclosed |
| US-7612087-B2 | Therapy for bacteria infections | NOVEXEL (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090215747-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | AVENTIS PHARMA S.A. (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20070299108-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2007-12-27 | — | — | US | disclosed |
| US-7112592-B2 | topical bactericides and disinfectants for surgical instruments; staphylococci; coliform bacteria; 7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide; bridged bicyclic ureas or carbamates having bridgehead nitrogen | AVENTIS PHARMA S.A. (FR) | 2006-09-26 | — | — | US | disclosed |
| US-20060189652-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2006-08-24 | — | — | US | disclosed |
| US-20060046995-A1 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2006-03-02 | — | — | US | disclosed |
| US-20050020572-A1 | Heterocyclic compounds as inhibitors of beta-lactamases | AVENTIS PHARMA S.A. (FR) | 2005-01-27 | — | — | US | disclosed |
| US-20030199541-A1 | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245254-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | KMT2A 1623/4885MEN1 814/4885MMP13 404/4885 |
| US-20110213147-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | KMT2A 3770/4885MEN1 434/4885MMP13 3849/4885 |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | KMT2A 1623/4885MEN1 814/4885MMP13 404/4885 |
| US-20070299108-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | KMT2A 3770/4885MEN1 434/4885MMP13 3849/4885 |
| US-20060046995-A1 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, SDHB, SDHA | KMT2A 3705/4885MEN1 137/4885MMP13 3468/4885 |
| US-20060189652-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | KMT2A 3770/4885MEN1 434/4885MMP13 3849/4885 |
| US-20050020572-A1 | Heterocyclic compounds as inhibitors of beta-lactamases | BACE1, GAA, CEL | KMT2A 1623/4885MEN1 814/4885MMP13 404/4885 |
| US-20110021772-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | KMT2A 3770/4885MEN1 434/4885MMP13 3849/4885 |
| US-20090215747-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | KMT2A 1623/4885MEN1 814/4885MMP13 404/4885 |
| US-20030199541-A1 | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents | AZI2, NISCH, DCTPP1 | KMT2A 2738/4885MEN1 107/4885MMP13 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.